Foghorn Therapeutics
(NASDAQ) FHTX
Foghorn Therapeutics Financials at a Glance
Market Cap
$349.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$28.22M
Net Income (TTM)
-$75.32M
EPS (TTM)
-$1.20
P/E Ratio
-4.94
Dividend
$0.00
Beta (Volatility)
1.61 (High)
Dividend
$0.00
Beta (Volatility)
1.61 (High)
Price
$5.95
Volume
293,968.361
Open
$5.95
Price
$5.95
Volume
293,968.361
Open
$5.95
Previous Close
$5.95
Daily Range
$5.66 - $6.06
52-Week Range
$3.27 - $6.95
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
1.61 (High)
Price
$5.95
Volume
293,968.361
Open
$5.95
Previous Close
$5.95
Daily Range
$5.66 - $6.06
52-Week Range
$3.27 - $6.95
Estimated Earnings Date
Aug 4, 2026
FHTX News
FHTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Foghorn Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
106
CEO
Adrian Gottschalk, MBA
Website
www.foghorntx.comHeadquarters
Cambridge, MA 02139, US
FHTX Financials
Key Financial Metrics (TTM)
Gross Margin
22.26%
Operating Margin
-286.16%
Net Income Margin
-266.88%
Return on Equity
85.78%
Return on Capital
N/A
Return on Assets
-33.90%
Earnings Yield
-20.24%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$349.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
58.71M
Volume
293.97K
Avg. Volume
221.92K
Financials (TTM)
Gross Profit
$6.28M
Operating Income
-$80.77M
EBITDA
-$72.53M
Operating Cash Flow
-$87.40M
Capital Expenditure
-$22.00K
Free Cash Flow
-$87.42M
Cash & ST Invst.
$184.88M
Total Debt
$41.99M
Foghorn Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$3.27M
-45.1%
Gross Profit
$3.03M
-49.1%
Gross Margin
92.72%
N/A
Market Cap
$349.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$3.12M
N/A
Employees
112
N/A
Net Income
-$19.88M
-5.5%
EBITDA
-$19.64M
-9.1%
Quarterly Fundamentals
Total Cash
$184.88M
-16.2%
Total Debt
$41.99M
+20.5%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$40.13M
+55.9%
Short Term Debt
$1.86M
-79.6%
Return on Assets
-33.90%
N/A
Return on Invested Capital
-51.20%
N/A
Free Cash Flow
-$25.27M
-5.3%
Operating Cash Flow
-$25.27M
-5.4%